A Validated Stability-Indicating Method for Separation of Prucalopride Drug by HPLC: Method Transfer to UPLC

References

• Higgins, P.D. and Johanson, J.F. (2004). Epidemiology of constipation in North America: a systematic review. Am. J. Gastroenterol. 99(4): 750-759. doi: 10.1111/j.1572-0241.2004.04114.x
   PubMed Web of Science ®Google Scholar
• Stewart, W.F., Liberman, J.N., Sandler, R.S., Woods, M.S., Stemhagen, A., Chee, E., Lipton, R.B., Farup, C.E. (1999). Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am. J. Gastroenterol. 94(12): 3530-40. doi: 10.1111/j.1572-0241.1999.01642.x
   PubMed Web of Science ®Google Scholar
• Loening-Baucke, V. (2007). Prevalence rates for constipation and faecal and urinary incontinence. Arch. Dis. Child. 92: 486-490. doi: 10.1136/adc.2006.098335
   PubMed Web of Science ®Google Scholar
• Bosshard, W., Dreher, R., Schnegg, J.F., Büla, C.J. (2004). The treatment of chronic constipation in elderly people: an update. Drugs Aging. 21(14): 911-30. doi: 10.2165/00002512-200421140-00002
   PubMed Web of Science ®Google Scholar
• Dennison, C., Prasad, M., Lloyd, A., Bhattacharyya, S.K., Dhawan, R. and Coyne, K. (2005). The health-related quality of life and economic burden of constipation. Pharmacoeconomics. 23(5): 461-76. doi: 10.2165/00019053-200523050-00006
   PubMed Web of Science ®Google Scholar
• Johanson, J.F. and Kralstein, J. (2007). Chronic constipation: a survey of the patient perspective. Aliment Pharmacol. Ther. 25(5): 599-608. doi: 10.1111/j.1365-2036.2006.03238.x
   PubMed Web of Science ®Google Scholar
• Irvine, E.J., Ferrazzi, S., Pare, P., Thompson, W.G. and Rance, L. (2002). Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am. J. Gastroenterol. 97(8): 1986-93. doi: 10.1111/j.1572-0241.2002.05843.x
   PubMed Web of Science ®Google Scholar
• Camilleri, M., Van Outryve, M.J., Beyens, G., Kerstens, R., Robinson, P. and Vandeplassche, L. (2010). Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol. Ther. 32(9): 1113-23. doi: 10.1111/j.1365-2036.2010.04455.x
   PubMed Web of Science ®Google Scholar
• Frampton, J.E. (2009). Prucalopride. Drugs. 69(17): 2463-2476. doi: 10.2165/11204000-000000000-00000
   PubMed Web of Science ®Google Scholar
• Tack, J., Stanghellini, V., Dubois, D., Joseph, A., Vandeplassche, L. and Kerstens, R. (2014). Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil. 26(1): 21-7. doi: 10.1111/nmo.12217
   PubMed Web of Science ®Google Scholar
• Tack, J. and Corsetti, M. (2012). Prucalopride: evaluation of the pharmacokinetics, pharmaco-dynamics, efficacy and safety in the treatment of chronic constipation. Expert Opin Drug Metab Toxicol. 8(10): 1327-1335. doi: 10.1517/17425255.2012.719497
   PubMed Web of Science ®Google Scholar
• Miner, P.B., Nichols, T. and Silvers, D.R. et al (1999). The efficacy and safety of prucalopride in patients with chronic constipation. Gastroenterology. 116(Suppl): A 1043.
   PubMedGoogle Scholar
• Quigley, E.M.M., Vandeplassche, L., Kerstens, R. and Ausma, J. (2009). Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol. Ther. 29(3): 315-28. doi: 10.1111/j.1365-2036.2008.03884.x
   PubMed Web of Science ®Google Scholar
• Pennant, M., Orlando, R., Barton, P., Bayliss, S., Routh, K. and Meads, C. (2011). Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief. Health Technol Assess. Suppl 1: 43-50. doi: 10.3310/hta15suppl1-05
   Google Scholar
• Chapman, H. and Pasternack, M. (2007). The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. European Journal of Pharmacology. 554: 98-105. doi: 10.1016/j.ejphar.2006.10.019
   PubMed Web of Science ®Google Scholar
• Briejer, M.R., Bosmans, J.P., Van Daele, P., Jurzak, M., Heylen, L., Leysen, J.E., Prins, N.H. and Schuurkes, J.A. (2001). The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur. J. Pharmacol. 423(1): 71-83. doi: 10.1016/S0014-2999(01)01087-1
   PubMed Web of Science ®Google Scholar
• European Medicines Agency EPAR (2009). https://www.ema.europa.eu/en/medicines/human/EPAR/resolor
   Google Scholar
• Health Canada, Notice of Decision for Resotran (2020) https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailOne.php?linkID=SBD00126
   Google Scholar
• Summary of product characteristics Resolor (prucalopride) October, (2009). 19. https://www.en.pdf. 1-34
   Google Scholar
• Gophane, V. and Thakur, R.A. (2016). Development, Validation and Stability Indicating RP-HPLC Method for Estimation of Prucalopride in Pharmaceutical Formulation. Inventi Rapid: Pharm. Analysis & Quality Assurance. 3: 1-8.
   Google Scholar
• Van de Velde, V., Vandeplassche, L., Hoppenbrouwers, M., Boterman, M. and Ausma. J. (2013). Effect of prucalopride on the pharmacokinetics of oral contraceptives in healthy women. Drugs R D. 13(1): 43-51. doi: 10.1007/s40268-013-0008-6
   PubMedGoogle Scholar
• Sun, Z., Zuo, L., Kang, J., Zhou, L., Jia, M., Li, Z., Yang, Z., Zhang, X. and Zhu, Z. (2016). Development and validation of a sensitive UHPLC-MS/MS method for quantitation of prucalopride in rat plasma and its application to pharmacokinetics study. J. Chromatogr B. 1033-1034: 328-333. doi: 10.1016/j.jchromb.2016.09.006
   PubMed Web of Science ®Google Scholar
• Zuo, L., Sun, Z., Wang, Z., Du, S., Kong, X., Li, L., Yang, J., Kang, J. and Zhang, X. (2016). Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry. J. Pharm. Biomed. Anal. 131: 246-255. doi: 10.1016/j.jpba.2016.08.030
   PubMed Web of Science ®Google Scholar
• Mahamuni, B.S., Jajula, A., Awasthi, A., Kalariya, P.D. and Talluri, M.V. (2016). Selective separation and characterisation of stress degradation products and process impurities of prucalopride succinate by LC-QTOF-MS/MS. J. Pharm. Biomed. Anal. 125: 219-28. doi: 10.1016/j.jpba.2016.03.047
   PubMed Web of Science ®Google Scholar
• ICH Guidelines, Q1A (R2) (2003). Stability testing of new drug substances and products (revision 2), in Proceedings of the International Conference on Harmonization.
   Google Scholar
• ICH, Q2 (R1) (2005). Validation of analytical procedure and methodology, In Proceeding of the International Conference on Harmonization, Geneva, Switzerland.
   Google Scholar
• Ravi, S.P., Madhuri, B., Naga, L.A., Pooja, A., Bhargava, S.M., Suresh, K. and Srinivasa B.P. (2020). Selected HPLC Applications - Quick Separation Guide: A Review. Int. J. Pharm. Sci. Rev. Res. 60(2): 13-20.
   Google Scholar
• Darasanapalli, M. and Maste, M. (2013). A Review on Ultra Performance Liquid Chromatography. Int. J. Drug Dev. & Res. 5(2): 29-34.
   Google Scholar
• Reddy, T.S., Balammal, G. and Saravana, A.K. (2012). Ultra performance liquid chromatography: an introduction and review. International Journal of Pharmaceutical Research & Analysis. 2(1): 24-31.
   Google Scholar